Skip to main content

Table 2 HIV transmission among 43 HIV-infected women who had two deliveries within the study.

From: Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: A cohort study

  Mother previously nevirapine un-exposed (first delivery) Mother previously nevirapine exposed (second delivery) p-value
Socio-demographic variables    
   Maternal age [mean ± SD] 25.3 ± 4.7 27.3 ± 4.9 < 0.0001
   Primipara [N (%)] 5 (12) 0 (0) /
HIV-related factors at enrolment    
   HIV viral load [median copies per ml (IQR)] 30,412 (6,864; 80,557) 18,918 (7,162; 78,152) 0.34
   CD4 cells per μl [median (IQR)] 430 (303, 595) 334 (188, 460) < 0.0001
   Disease stage III [N (%)] 14 (33) 9 (21) 0.30
   BMI at 1 month post partum [mean ± SD] 21.4 ± 2.8 22.4 ± 3.1 0.007
   Hemoglobin [g/dl] [mean ± SD] 10.7 ± 1.5 11.0 ± 1.4 0.24
   Positive rapid plasma regain test for syphilis [N (%)] 9 (22) 5 (12) 0.22
Obstetric and infant variables    
   Caesarean sections [N (%)] 2 (5) 0 (0) /
   Low birth weight [N (%) < 2500 g] 5 (12) 2 (5) 0.45
   Birth weight [mean ± SD] 3029 ± 536 3042 ± 469 0.82
   Preterm delivery [N (%) ≤ 34 weeks of gestation] 5 (12) 8 (19) 0.75
   Sex [N (%) male] 23 (53) 16 (37) 0.14
Nevirapine prophylaxis at current delivery    
   Maternal dose taken [N (%)] 43 (100) 43 (100) /
   Infant dose taken [N (%)] 40 (93) 41 (98) 1.0
HIV transmission and infant mortality    
   Infants HIV positive ≤ day 42 [N (%)] 3 (7) 3 (7) 1.0
   Infants HIV positive or died ≤ day 42 [N (%)] 4 (9) 3 (7) 1.0
  1. Numbers may differ from the total due to missing data